Stoke Therapeutics’ (STOK) Buy Rating Reiterated at Chardan Capital

Chardan Capital reissued their buy rating on shares of Stoke Therapeutics (NASDAQ:STOK) in a research note published on Wednesday morning,Benzinga reports. Chardan Capital currently has a $24.00 price objective on the stock.

STOK has been the subject of a number of other reports. HC Wainwright lifted their price target on Stoke Therapeutics from $35.00 to $47.00 and gave the stock a “buy” rating in a report on Tuesday, February 18th. Needham & Company LLC restated a “buy” rating and set a $22.00 target price on shares of Stoke Therapeutics in a research note on Tuesday. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Stoke Therapeutics in a report on Tuesday, December 10th. One analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, Stoke Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $23.00.

Stoke Therapeutics Stock Down 2.2 %

Shares of NASDAQ:STOK opened at $8.15 on Wednesday. Stoke Therapeutics has a fifty-two week low of $5.93 and a fifty-two week high of $17.58. The firm’s 50 day moving average price is $9.47 and its 200 day moving average price is $11.45. The stock has a market cap of $431.68 million, a price-to-earnings ratio of -3.88 and a beta of 0.99.

Stoke Therapeutics (NASDAQ:STOK) last announced its quarterly earnings data on Monday, March 24th. The company reported ($0.18) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.56) by $0.38. The business had revenue of $22.61 million for the quarter, compared to analyst estimates of $4.20 million. Stoke Therapeutics had a negative net margin of 629.90% and a negative return on equity of 54.45%. On average, equities analysts anticipate that Stoke Therapeutics will post -2.01 EPS for the current year.

Insider Buying and Selling at Stoke Therapeutics

In other news, insider Barry Ticho sold 3,884 shares of Stoke Therapeutics stock in a transaction on Tuesday, March 18th. The shares were sold at an average price of $8.67, for a total value of $33,674.28. Following the transaction, the insider now directly owns 63,962 shares of the company’s stock, valued at $554,550.54. The trade was a 5.72 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Edward M. Md Kaye sold 10,382 shares of the stock in a transaction on Tuesday, March 18th. The stock was sold at an average price of $8.67, for a total transaction of $90,011.94. Following the sale, the director now owns 148,253 shares of the company’s stock, valued at approximately $1,285,353.51. This represents a 6.54 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 16,532 shares of company stock worth $143,332. 11.30% of the stock is owned by insiders.

Hedge Funds Weigh In On Stoke Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Bank of New York Mellon Corp lifted its holdings in shares of Stoke Therapeutics by 1.4% during the fourth quarter. Bank of New York Mellon Corp now owns 93,195 shares of the company’s stock worth $1,028,000 after purchasing an additional 1,330 shares during the period. Graham Capital Management L.P. raised its position in Stoke Therapeutics by 8.5% during the 4th quarter. Graham Capital Management L.P. now owns 18,634 shares of the company’s stock worth $206,000 after buying an additional 1,453 shares during the last quarter. Gilder Gagnon Howe & Co. LLC raised its position in Stoke Therapeutics by 2.0% during the 4th quarter. Gilder Gagnon Howe & Co. LLC now owns 92,546 shares of the company’s stock worth $1,021,000 after buying an additional 1,791 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its stake in shares of Stoke Therapeutics by 6.3% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 37,455 shares of the company’s stock worth $414,000 after acquiring an additional 2,215 shares during the period. Finally, Rhumbline Advisers boosted its holdings in shares of Stoke Therapeutics by 6.0% in the fourth quarter. Rhumbline Advisers now owns 49,374 shares of the company’s stock valued at $545,000 after acquiring an additional 2,787 shares in the last quarter.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.